Clinical trials: Stage III Non-Small Cell Lung Cancer AJCC v7
Carcinoma, Non-Small-Cell Lung
Study to Evaluate Using Nelfinavir With Chemoradiation for Non-small Cell Lung Cancer
This study combines nelfinavir (NFV) with radiation therapy and chemotherapy as a treatment for non-small cell lung cancer (NSCLC) who are considered candidates for pre-operative treatment.
- Trial name
- NCT00791336
- Testing
- Nelfinavir
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Iowa
Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage II Lung Non-Small Cell Cancer AJCC v7
Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial)
This phase III ALCHEMIST treatment trial studies how well nivolumab after surgery and chemotherapy work in treating patients with stage IB-IIIA non-small cell lung cancer.
- Conditions
- Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage II Lung Non-Small Cell Cancer AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7
- Trial name
- ANVIL (NCT02595944)
- Testing
- Biospecimen Collection, Computed Tomography, Echocardiography Test
- Where
- 884 sites in United States
- Volunteers
- 903 people
- Sponsor
- National Cancer Institute (NCI)
Non Small Cell Lung Cancer Metastatic, Lung Diseases
PALACE: Cemiplimab Trial According to ctDNA Levels
This is an open-label, non-randomised, phase II, multicenter clinical trial. 63 stage IV or stage IIIB/C not candidates for definitive chemo/radiotherapy or surgical resection non-small cell lung cancer (NSCLC) per the 8th…
- Conditions
- Non Small Cell Lung Cancer Metastatic, Lung Diseases, Stage IV Non-small Cell Lung Cancer, Stage III Non-small Cell Lung Cancer
- Trial name
- PALACE (NCT06917573)
- Testing
- Cemiplimab, Carboplatin, Paclitaxel
- Where
- 20 sites in Spain
- Volunteers
- 63 people
- Sponsor
- Fundación GECP
Locally Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Stage III Lung Adenocarcinoma AJCC v7
Methoxyamine Hydrochloride, Pemetrexed Disodium, Cisplatin, and Radiation Therapy in Treating Patients With Stage IIIA-IV Non-small Cell Lung Cancer
This phase I trial studies the side effects and best dose of methoxyamine when given together with pemetrexed disodium, cisplatin, and radiation therapy in treating patients with stage IIIA-IV non-small cell lung cancer.
- Conditions
- Locally Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Stage III Lung Adenocarcinoma AJCC v7, Stage III Lung Large Cell Carcinoma AJCC v7, Stage III Lung Non-Small Cell Cancer AJCC v7
- Trial name
- NCT02535325
- Testing
- 3-Dimensional Conformal Radiation Therapy, Cisplatin, Intensity-Modulated Radiation Therapy
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- National Cancer Institute (NCI)
Stage III Non-small-cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Heterogeneously Hypofractionated Radiotherapy for Locally Advanced NSCLC
The options for patients with locally advanced non-small cell lung cancer (NSCLC) who are not candidates for a standard definitive chemoradiotherapy regime are meagre.
- Conditions
- Stage III Non-small-cell Lung Cancer, Stage IV Non-small Cell Lung Cancer, Radiotherapy Side Effect
- Trial name
- NCT03742687
- Testing
- Heterogeneously Hypofractionated Radiotherapy
- Where
- Denmark
- Volunteers
- 151 people
- Sponsor
- Danish Lung Cancer Group
Carcinoma, Non-Small-Cell Lung
A Trial of Sugemalimab and Chemotherapy in Unresectable Stage III NSCLC
The goal of this phase II, open-label, single-arm study is to evaluate the efficacy and safety of induction immunotherapy and chemotherapy followed by the multidisciplinary team (MDT)-guided radiotherapy or surgery in…
- Trial name
- NCT05940532
- Testing
- Sugemalimab and Chemotherapy
- Where
- China
- Volunteers
- 41 people
- Sponsor
- Hunan Cancer Hospital
NSCLC, Stage III
Using Circulating Tumor DNA to Personalize Duration of Consolidation Durvalumab
This research aims to incorporate ctDNA analysis into clinical practice to individualize therapy in patients with stage III NSCLC by moving to a treatment-by-marker based approach (as opposed to treatment based on clinical or…
- Trial name
- NCT05757843
- Testing
- Signatera ctDNA test, Durvalumab
- Sponsor
- Indiana University
Stage III Non-small-cell Lung Cancer
Omitting Clinical Target Volume of Unresectable Stage III Non-small-cell Lung Cancer.
About 20-30% of patients with stage III non-small cell lung cancer (NSCLC) are unresectable and definitive concurrent radiochemotherapy is the standard care.
- Trial name
- NCT05331833
- Testing
- The enrollment was randomly (1:1) assigned into the study group with CTV-omitted IMRT under PET-CT guidance and the control group with CTV-delineated IMRT using a random number table.
- Volunteers
- 90 people
- Sponsor
- Jianguo Sun
Lung Cancer
Docetaxel and Cisplatin in Treating Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer That Has Been Completely Removed By Surgery
RATIONALE: Drugs used in chemotherapy, such as docetaxel and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00281970
- Testing
- cisplatin, docetaxel, adjuvant therapy
- Where
- 3 sites in United States
- Volunteers
- 50 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Lung Cancer
S0424 - Carcinogens in Lung Tissue From Smokers (Closed to Entry as of 7/15/07) and Non-Smokers With Newly Diagnosed Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer
RATIONALE: Studying samples of blood and tissue from smokers (closed to entry as of 7/15/07) and non-smokers with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers…
- Trial name
- NCT00450281
- Testing
- chromogenic in situ hybridization, gene expression analysis, mutation analysis
- Where
- 405 sites in United States
- Volunteers
- 981 people
- Sponsor
- SWOG Cancer Research Network
Lung Cancer
Chemotherapy Plus Radiation Therapy in Treating Patients With Stage I, Stage II, or Stage III Non-small Cell Lung Cancer That Cannot Be Surgically Removed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy used high-energy x-rays to damage tumor cells.
- Trial name
- NCT00003803
- Testing
- cisplatin, gemcitabine hydrochloride, radiation therapy
- Where
- 17 sites in Belgium, France and 3 more
- Volunteers
- 158 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Extensive Stage Small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer
FR901228 in Treating Patients With Refractory or Progressive Small Cell Lung Cancer or Non-small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of FR901228 in treating patients who have refractory or…
- Conditions
- Extensive Stage Small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer, Recurrent Small Cell Lung Cancer
- Trial name
- NCT00020202
- Testing
- FR901228
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Stage III Non-small Cell Lung Cancer
Study of Tislelizumab for Locally Advanced Non-Small Cell Lung Cancer Following Neoadjuvant Chemotherapy Plus Tislelizumab ± Bevacizumab and Definitive Concurrent Chemoradiation Therapy
The phase II Study is to explore the efficacy and safety of Tislelizumab as consolidation therapy in patients with locally advanced non-small cell lung cancer who have not progressed following neoadjuvant chemotherapy plus…
- Trial name
- NCT05468242
- Testing
- Neoadjuvant chemo-immunotherapy, Bevacizumab, Radiotherapy
- Where
- China
- Volunteers
- 116 people
- Sponsor
- Sun Yat-sen University
Stage III Non-Small Cell Lung Cancer AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7
Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer
This randomized phase II trial studies how well erlotinib hydrochloride or crizotinib with chemoradiation therapy works in treating patients with stage III non-small cell lung cancer.
- Conditions
- Stage III Non-Small Cell Lung Cancer AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7, Stage IIIB Non-Small Cell Lung Cancer AJCC v7
- Trial name
- NCT01822496
- Testing
- Radiation Therapy, Carboplatin, Cisplatin
- Where
- 174 sites in United States
- Volunteers
- 59 people
- Sponsor
- National Cancer Institute (NCI)
Lung Cancer
Combination Chemotherapy and Computer-Planned Radiation Therapy in Treating Patients With Unresectable Stage III Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00033553
- Testing
- carboplatin, gemcitabine hydrochloride, paclitaxel
- Where
- 74 sites in United States
- Volunteers
- 69 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Non-small Cell Lung Cancer (NSCLC) Stage III
Anti-cancer MUC1-specific Immunotherapy for Unresectable Stage III Non-small Cell Lung Cancer
Phase Ib study investigating whether liposome BLP25 mucin-1 (MUC1) peptide-specific immunotherapy (L-BLP25) administered as weekly subcutaneous doses over 8 weeks following a single dose of intravenous cyclophosphamide (CPA)…
- Trial name
- FINGERPRINT (NCT01731587)
- Testing
- Biological: MUC1 peptide specific immunotherapy, Cyclophosphamide (CPA)
- Sponsor
- Merck KGaA, Darmstadt, Germany
Lung Cancer
Chemotherapy and Radiation Therapy With or Without Efaproxiral in Treating Patients With Stage III Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00055887
- Testing
- carboplatin, cisplatin, efaproxiral
- Where
- 22 sites in United States, Belgium and 2 more
- Sponsor
- Spectrum Pharmaceuticals, Inc
Non-Small Cell Lung Cancer
Bevacizumab and Carboplatin/Paclitaxel and Radiation in Non-Small Cell Lung Cancer
This study is being done to learn what effects (good and bad) bevacizumab in conjunction with carboplatin/paclitaxel and radiation therapy has on patients with non-small cell lung cancer (NSCLC).
- Trial name
- NCT00578149
- Testing
- Bevacizumab, Carboplatin, Paclitaxel
- Where
- 2 sites in United States
- Volunteers
- 45 people
- Sponsor
- Dana-Farber Cancer Institute
Lung Cancer, Non-small Cell Carcinoma
Durvalumab Followed by Chemoradiation and Consolidation Durvalumab for Stage III Non-small Cell Lung Cancer
Single arm study of induction durvalumab (1500 mg IV) for 1 cycle (every 4 weeks), administered prior to starting concurrent definitive chemoradiation, followed by consolidation durvalumab (1500 mg IV every 4 weeks) for up to 12…
- Trial name
- NCT04364048
- Testing
- Induction Durvalumab, Chemotherapy, Radiation
- Where
- 5 sites in United States
- Volunteers
- 10 people
- Sponsor
- Rachel Sanborn
Lung Cancer
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00004093
- Testing
- carboplatin, Gemcitabine, paclitaxel
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Northwestern University